Structural insights into the role and targeting of EGFRvIII
- PMID: 38908376
- DOI: 10.1016/j.str.2024.05.018
Structural insights into the role and targeting of EGFRvIII
Abstract
The epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung and other cancers. In glioblastoma multiforme (GBM), the EGFR deletion variant III (EGFRvIII) is frequently found alongside EGFR amplification. Agents targeting the EGFR axis have shown limited clinical benefits in GBM and the role of EGFRvIII in GBM is poorly understood. To shed light on the role of EGFRvIII and its potential as a therapeutic target, we determined X-ray crystal structures of a monomeric EGFRvIII extracellular region (ECR). The EGFRvIII ECR resembles the unliganded conformation of EGFR, including the orientation of the C-terminal region of domain II. Domain II is mostly disordered, but the ECR structure is compact. We selected a nanobody with preferential binding to EGFRvIII relative to EGFR and structurally defined an epitope on domain IV that is occluded in the unliganded intact EGFR. These findings suggest new avenues for EGFRvIII targeting in GBM.
Keywords: VHH domain; X-ray crystallography; epidermal growth factor receptor; epidermal growth factor receptor variant III; glioblastoma multiforme; nanobody; oncogenic mutation.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.e.K. is an employee at TerThera and R.C.R. is an employee of Lava Therapeutics.
Similar articles
-
The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Eur J Pharmacol. 2017 Sep 5;810:70-82. doi: 10.1016/j.ejphar.2017.05.064. Epub 2017 Jun 2. Eur J Pharmacol. 2017. PMID: 28583430 Review.
-
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. FEBS J. 2013. PMID: 23777544 Review.
-
125I-Labeled monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).2010 Jul 1 [updated 2010 Aug 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Jul 1 [updated 2010 Aug 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20698072 Free Books & Documents. Review.
-
111In-Labeled CHX-A”-DTPA conjugated monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII).2010 Jul 1 [updated 2010 Aug 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Jul 1 [updated 2010 Aug 5]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20698071 Free Books & Documents. Review.
-
The EGFRvIII variant in glioblastoma multiforme.J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. J Clin Neurosci. 2009. PMID: 19324552 Review.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
